feed,title,long_url,short_url
Benzinga,"APi Group Stock Gains After Q3 Results, Clocks 13% Organic Revenue Growth",https://benzinga.com/news/earnings/21/11/24019820/api-group-stock-gains-after-q3-results-clocks-13-organic-revenue-growth,https://j.mp/30fwTlm
Benzinga,"Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters",https://benzinga.com/general/biotech/21/11/24019825/hit-by-slow-rollout-biogens-aduhelm-could-soon-find-itself-in-price-competition-reuters,https://j.mp/31QnmSo
Benzinga,Why Did Mizuho Upgrade This Biotech Stock Focused On Age-Related Eye Diseases?,https://benzinga.com/general/biotech/21/11/24019098/why-did-mizuho-upgrade-this-biotech-stock-focused-on-age-related-eye-diseases,https://j.mp/3qnXgQX
Benzinga,Freeline Therapeutics Touts Encouraging Data From Fabry Disease Program,https://benzinga.com/general/biotech/21/11/24017786/freeline-therapeutics-touts-encouraging-data-from-fabry-disease-program,https://j.mp/3D41Ya5
